Novartis has stopped development of its CAR-T therapy rap-cel across multiple indications after side effects were observed during testing. Bristol Myers Squibb has also voluntarily paused its zola-cel program over safety concerns. Results published in February reported one case of IEC-HS in a Phase 1 study of zola-cel. Kyverna Therapeutics could file for approval in stiff person syndrome by year-end and is enrolling patients for a pivotal myasthenia gravis study.